Heart Failure Clinical Trial
A Study to Assess the Hemodynamic Effects, Safety, Tolerability, and Pharmacokinetics of Intravenous APD418 in Adult Participants With Heart Failure With Reduced Ejection Fraction
The purpose of this study is to evaluate the safety, pharmacokinetics, and effect on cardiac function of intravenous APD418 in adult participants with heart failure with reduced ejection fraction (HFrEF).
This study has an adaptive design, in which dose escalation in Part A will inform dose expansion in Part B. Part A is a single-ascending dose, placebo-controlled study planned to consist of 5 cohorts evaluating 5 doses of APD418. Part B is a parallel-treatment group study planned to evaluate 2 doses of APD418 and placebo. Participants in Part A cannot participate in Part B.
Advanced chronic Heart Failure with Reduced Ejection Fraction (HFrEF), defined as left ventricular ejection fraction (LVEF) less than or equal to (≤) 35% at Screening, including documented history of HFrEF (LVEF ≤ 35%) for at least 4 months prior to Screening
New York Heart Association Class II-IV
Cardiac index ≤ 2.5 liters per minute per square meter (L/min/m^2) and pulmonary capillary wedge pressure ≥ 15 millimeters of mercury (mm Hg) at Day 1
Body mass index 18.0 to 37.0 kilograms per square meter (kg/m^2), inclusive, and body weight < 150 kg at Screening and Day 1
Hemodynamically unstable at Day 1 or in the opinion of the Investigator likely to progress to becoming hemodynamically unstable during the course of the study
Treated with carvedilol or at a dose higher than a total of 25 milligrams per day any time within 72 hours of Day 1 through the end of the in-clinic observation Post-dose Period.
Receiving any mechanical (respiratory or circulatory) or renal support therapy at Screening or Day 1
Systolic Blood Pressure ≤ 90 millimeter of mercury (mm Hg) or ≥ 160 mm Hg, or Heart Rate < 50 beats per minute (bpm) or > 110 bpm, at Screening or Day 1
Recently treated with inotropic, intravenous (IV) vasoactive or IV diuretic therapy, or expected to require such therapy with these drugs any time from Day 1 through the end of study conduct.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 21 Locations for this study
Tampa Florida, 33612, United States
Peoria Illinois, 61606, United States
Houston Texas, 77030, United States
Salt Lake City Utah, 84132, United States
Madison Wisconsin, 53792, United States
Bernau bei Berlin Brandenburg, 16321, Germany
Bad Nauheim , 61231, Germany
Greifswald , 17475, Germany
Nea Ionia Athens, 14233, Greece
Pylaia Thessaloniki, 55535, Greece
Larissa , 41110, Greece
Gniezno , 62-20, Poland
Krakow , 31-20, Poland
Wroclaw , 50-55, Poland
Belgrade , 11 07, Serbia
Belgrade , 11000, Serbia
Belgrade , 11040, Serbia
Belgrade , 11080, Serbia
Kragujevac , 34000, Serbia
Sremska Kamenica , 21204, Serbia
Užice , 31000, Serbia
How clear is this clinincal trial information?
Introducing, the Journey Bar
Use this bar to access information about the steps in your cancer journey.